Takeda sheds products, 485 jobs in deals worth $5.7B

After taking on some $30 billion of debt to acquire local drugmaker Shire plc earlier this year, Takeda Pharmaceutical Co. Ltd. is paying off some of that bill by selling two products for a combined $5.7 billion. A Japanese drugmaker which has a large presence in Lexington and Cambridge, Takeda (NYSE: TAK) is selling the dry eye treatment Xiidra to Novartis for $3.4 billion upfront, with another $1.9 available in potential milestone payments, the latter disclosed after markets closed Wednesday.…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news